Defining EGFR amplification status for clinical trial inclusion
暂无分享,去创建一个
M. J. van den Bent | M. Weller | T. Gorlia | P. Ansell | P. French | J. Kros | M. Eoli | E. Franceschi | E. Bain | A. Walenkamp | J. Sepúlveda | P. Clement | J. Frenel | I. D. de Heer | J. Looman | M. Morfouace
[1] Jong-Hee Chang,et al. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases , 2019, Journal of Neuro-Oncology.
[2] T. Mikkelsen,et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial , 2018, Neuro-oncology.
[3] P. French,et al. Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas , 2018, Cancers.
[4] M. J. van den Bent,et al. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma , 2018, Neuro-oncology.
[5] A. Tolcher,et al. Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor , 2018, Cancer.
[6] Hao Xiong,et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study , 2017, Cancer Chemotherapy and Pharmacology.
[7] Act Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .
[8] G. Reifenberger,et al. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors , 2017, Clinical Cancer Research.
[9] Jessica M. Rusert,et al. Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity , 2017, Nature.
[10] In-Hee Lee,et al. Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.
[11] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[12] M. J. van den Bent,et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. , 2015, Neuro-oncology.
[13] Jun Yao,et al. Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. , 2015, Cancer research.
[14] Marc Choisy,et al. Determination of cut-off cycle threshold values in routine RT–PCR assays to assist differential diagnosis of norovirus in children hospitalized for acute gastroenteritis , 2015, Epidemiology and Infection.
[15] Na Li,et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.
[16] M. J. van den Bent,et al. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). , 2014 .
[17] S. Nelson,et al. Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.
[18] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[19] J. Pollack,et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms , 2013, Oncogene.
[20] W. Curran,et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. , 2013, International journal of radiation oncology, biology, physics.
[21] Paul S Mischel,et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.
[22] Rebecca A Betensky,et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.
[23] C. James,et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. , 2011, International journal of radiation oncology, biology, physics.
[24] Susan M. Chang,et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.
[25] M. J. van den Bent,et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[27] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.